Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07601243 · ClinicalTrials.gov registry record · Phase 1
Study of GS-2426 in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
NCT07601243 is a Phase 1 study that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 174 participants.
The verdict
NCT07601243, a Phase 1 study, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
Study Summary
The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in participants with MTAP-deleted advanced solid tumors and to determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended phase II dose (RP2D).
Interventions
- DRUG GS-2426
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2026-06-02 |
| Est. Completion | 2029-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07601243
The ClinicalTrials.gov registry entry for NCT07601243 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GS-2426 is the first listed.
NCT07601243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07601243 about?
NCT07601243 is a clinical study titled "Study of GS-2426 in Participants With Advanced Solid Tumors". The goal of this clinical study is to learn more about the study drug GS-2426, and how safe and tolerable it is in participants with advanced methylthioadenosine phosphorylase (MTAP)-deleted solid tumors. The primary objective of this study is to evaluate the safety and tolerability of GS-2426 in p...
What is the current status of trial NCT07601243?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2026-06-02. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07601243?
The interventions under investigation include: GS-2426 (DRUG).
Who is sponsoring clinical trial NCT07601243?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.